fampridine Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
4163 504-24-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fampyra
  • dalfampridine
  • ampyra
  • pyridin-4-amine
  • 4-aminopyridine
  • fampridine
One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes.
  • Molecular weight: 94.12
  • Formula: C5H6N2
  • CLOGP: 0.32
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 38.91
  • ALOGS: 0.46
  • ROTB: 0

Drug dosage:

DoseUnitRoute
20 mg O

Approvals:

DateAgencyCompanyOrphan
Jan. 22, 2010 FDA ACORDA

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary tract infection 2338.97 35.69 705 6556 30623 3347975
Gait disturbance 2332.78 35.69 686 6575 27306 3351292
Drug ineffective 2094.15 35.69 910 6351 115180 3263418
Laboratory test abnormal 1635.78 35.69 377 6884 5467 3373131
Balance disorder 1302.49 35.69 366 6895 12073 3366525
Multiple sclerosis relapse 1166.92 35.69 333 6928 11597 3367001
Insomnia 1042.78 35.69 400 6861 35498 3343100
Fall 991.14 35.69 444 6817 58439 3320159
Dizziness 954.88 35.69 469 6792 76043 3302555
Seizure 697.71 35.69 311 6950 40089 3338509
Urine analysis abnormal 658.43 35.69 124 7137 589 3378009
Inappropriate schedule of drug administration 652.51 35.69 221 7040 13532 3365066
Muscular weakness 596.66 35.69 229 7032 20112 3358486
Therapy cessation 567.56 35.69 148 7113 3601 3374997
Multiple sclerosis 523.88 35.69 158 7103 6610 3371988
Asthenia 458.12 35.69 275 6986 65390 3313208
Headache 438.57 35.69 303 6958 91677 3286921
Fatigue 430.40 35.69 318 6943 106922 3271676
Therapeutic response unexpected 422.90 35.69 126 7135 5042 3373556
Adverse drug reaction 350.03 35.69 126 7135 9185 3369413
Nausea 328.06 35.69 294 6967 129351 3249247
Constipation 320.20 35.69 168 7093 30644 3347954
Gait inability 309.93 35.69 109 7152 7416 3371182
Drug dose omission 306.75 35.69 176 7085 38256 3340342
Back pain 284.56 35.69 167 7094 37838 3340760
Paraesthesia 274.17 35.69 146 7115 27402 3351196
Memory impairment 262.96 35.69 117 7144 14821 3363777
Escherichia urinary tract infection 248.23 35.69 62 7199 1255 3377343
Feeling abnormal 246.36 35.69 136 7125 27389 3351209
B-lymphocyte count decreased 235.10 35.69 42 7219 138 3378460
Hypoaesthesia 217.01 35.69 121 7140 24818 3353780
Muscle spasms 205.80 35.69 120 7141 26783 3351815
Tremor 203.39 35.69 121 7140 28023 3350575
Depression 190.66 35.69 132 7129 39638 3338960
Urine leukocyte esterase positive 189.55 35.69 34 7227 115 3378483
Condition aggravated 182.87 35.69 128 7133 39105 3339493
Walking aid user 180.99 35.69 44 7217 792 3377806
Culture urine positive 174.06 35.69 40 7221 558 3378040
Malaise 170.16 35.69 151 7110 65026 3313572
Flushing 169.56 35.69 85 7176 14028 3364570
Movement disorder 165.75 35.69 57 7204 3614 3374984
Pain in extremity 165.51 35.69 132 7129 49080 3329518
Dysuria 157.37 35.69 63 7198 6119 3372479
Burning sensation 154.16 35.69 69 7192 8835 3369763
Muscle spasticity 153.37 35.69 50 7211 2686 3375912
Generalised tonic-clonic seizure 141.39 35.69 63 7198 7979 3370619
Mobility decreased 140.70 35.69 67 7194 9881 3368717
Dysstasia 137.07 35.69 50 7211 3766 3374832
Pollakiuria 137.03 35.69 55 7206 5375 3373223
Trigeminal neuralgia 133.73 35.69 34 7227 740 3377858
Musculoskeletal stiffness 127.53 35.69 70 7191 13880 3364718
White blood cells urine positive 125.75 35.69 29 7232 411 3378187
Cystitis 123.91 35.69 51 7210 5315 3373283
Dysgraphia 121.95 35.69 31 7230 674 3377924
Micturition urgency 121.87 35.69 37 7224 1570 3377028
Full blood count abnormal 121.14 35.69 28 7233 401 3378197
Lymphocyte count decreased 118.51 35.69 46 7215 4113 3374485
Urinary incontinence 118.32 35.69 51 7210 5961 3372637
JC polyomavirus test positive 117.83 35.69 26 7235 298 3378300
Drug effect decreased 117.58 35.69 63 7198 11906 3366692
Abdominal discomfort 115.34 35.69 73 7188 18811 3359787
Confusional state 113.06 35.69 95 7166 37903 3340695
Wheelchair user 112.98 35.69 28 7233 547 3378051
Cognitive disorder 111.22 35.69 53 7208 7821 3370777
Epilepsy 108.13 35.69 50 7211 6895 3371703
Pain 104.15 35.69 121 7140 71436 3307162
CD4 lymphocytes increased 102.24 35.69 19 7242 82 3378516
Peroneal nerve palsy 100.42 35.69 29 7232 1032 3377566
Influenza like illness 100.37 35.69 61 7200 14626 3363972
Glycosylated haemoglobin increased 100.05 35.69 37 7224 2895 3375703
Head injury 98.05 35.69 44 7217 5659 3372939
Pruritus 97.86 35.69 96 7165 46737 3331861
T-lymphocyte count increased 88.31 35.69 15 7246 33 3378565
Red blood cell count decreased 84.40 35.69 41 7220 6307 3372291
T-lymphocyte count decreased 83.93 35.69 17 7244 124 3378474
Haemoglobin urine present 83.33 35.69 14 7247 28 3378570
Vitamin B12 increased 80.07 35.69 16 7245 108 3378490
Loss of consciousness 78.80 35.69 68 7193 28079 3350519
Central nervous system lesion 77.81 35.69 30 7231 2631 3375967
Haematocrit decreased 77.58 35.69 41 7220 7526 3371072
Urine abnormality 75.26 35.69 20 7241 520 3378078
Stress 75.16 35.69 40 7221 7446 3371152
Red blood cells urine positive 73.69 35.69 17 7244 241 3378357
Secondary progressive multiple sclerosis 72.60 35.69 18 7243 352 3378246
Dyspepsia 72.56 35.69 46 7215 11866 3366732
Speech disorder 70.37 35.69 41 7220 9091 3369507
Hip fracture 69.06 35.69 34 7227 5381 3373217
Diarrhoea 68.85 35.69 121 7140 104227 3274371
Protein urine present 68.77 35.69 22 7239 1110 3377488
Feeling hot 67.94 35.69 38 7223 7798 3370800
Urine odour abnormal 67.80 35.69 20 7241 767 3377831
Neurogenic bladder 67.54 35.69 19 7242 614 3377984
Vertigo 66.11 35.69 43 7218 11589 3367009
Hypokinesia 64.82 35.69 25 7236 2194 3376404
Adverse event 63.91 35.69 42 7219 11515 3367083
Contusion 62.91 35.69 46 7215 14964 3363634
Vomiting 61.86 35.69 106 7155 89425 3289173
Loss of personal independence in daily activities 61.04 35.69 31 7230 5239 3373359
Discomfort 60.24 35.69 33 7228 6503 3372095
Status epilepticus 59.88 35.69 27 7234 3508 3375090
Depressed mood 59.75 35.69 33 7228 6608 3371990
Amnesia 59.36 35.69 39 7222 10687 3367911
Urinary retention 58.35 35.69 34 7227 7538 3371060
Extra dose administered 57.06 35.69 20 7241 1339 3377259
Medication error 55.77 35.69 39 7222 11832 3366766
Initial insomnia 55.70 35.69 18 7243 938 3377660
Urinary sediment present 55.24 35.69 12 7249 127 3378471
Tongue biting 54.61 35.69 15 7246 443 3378155
Anxiety 54.18 35.69 65 7196 39564 3339034
Vision blurred 54.13 35.69 47 7214 19542 3359056
CD8 lymphocytes decreased 53.86 35.69 11 7250 84 3378514
Arthralgia 52.85 35.69 80 7181 60781 3317817
Escherichia test positive 52.24 35.69 14 7247 376 3378222
Dyskinesia 51.65 35.69 31 7230 7254 3371344
Neutrophil count increased 50.89 35.69 25 7236 3935 3374663
Abdominal pain upper 49.96 35.69 50 7211 24866 3353732
Urinary tract infection bacterial 49.39 35.69 14 7247 465 3378133
Rash 49.07 35.69 84 7177 70737 3307861
Lymphocyte percentage decreased 48.91 35.69 14 7247 482 3378116
Bacterial test positive 47.71 35.69 16 7245 937 3377661
Nasopharyngitis 47.64 35.69 46 7215 21901 3356697
CD4 lymphocytes decreased 46.88 35.69 15 7246 757 3377841
White blood cell count decreased 46.26 35.69 48 7213 24899 3353699
Alopecia 43.50 35.69 41 7220 18945 3359653
Blood immunoglobulin M decreased 43.14 35.69 10 7251 145 3378453
Muscle tightness 42.92 35.69 19 7242 2362 3376236
Syncope 41.67 35.69 46 7215 25587 3353011
Coordination abnormal 41.08 35.69 20 7241 3086 3375512
Red blood cell count abnormal 40.80 35.69 10 7251 186 3378412
Mean cell haemoglobin decreased 40.74 35.69 11 7250 304 3378294
Sleep disorder 40.65 35.69 28 7233 8285 3370313
Urinary tract infection pseudomonal 40.02 35.69 10 7251 202 3378396
Laceration 39.15 35.69 21 7240 3967 3374631
Throat irritation 38.75 35.69 23 7238 5271 3373327
Eye movement disorder 38.29 35.69 16 7245 1728 3376870
Urine ketone body present 38.25 35.69 11 7250 385 3378213
Middle insomnia 38.19 35.69 16 7245 1740 3376858
Migraine 38.16 35.69 29 7232 9987 3368611
Blood glucose increased 37.58 35.69 38 7223 19117 3359481
Vitamin D decreased 37.39 35.69 14 7247 1132 3377466
Oropharyngeal pain 37.15 35.69 31 7230 12203 3366395
Gait spastic 37.15 35.69 8 7253 81 3378517
Lymphocyte count abnormal 36.06 35.69 9 7252 181 3378417

Pharmacologic Action:

SourceCodeDescription
ATC N07XX07 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
OTHER NERVOUS SYSTEM DRUGS
Other nervous system drugs
FDA EPC N0000192795 Potassium Channel Blocker
FDA MoA N0000175448 Potassium Channel Antagonists
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D026902 Potassium Channel Blockers
CHEBI has role CHEBI:71031 orphan drug
CHEBI has role CHEBI:33289 avicide

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Multiple sclerosis indication 24700007 DOID:2377
Seizure disorder contraindication 128613002 DOID:1826
Impaired renal function disorder contraindication 197663003

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.58 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG AMPYRA ACORDA N022250 Jan. 22, 2010 RX TABLET, EXTENDED RELEASE ORAL 5540938 July 30, 2018 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
10MG AMPYRA ACORDA N022250 Jan. 22, 2010 RX TABLET, EXTENDED RELEASE ORAL 8663685 Jan. 18, 2025 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
10MG AMPYRA ACORDA N022250 Jan. 22, 2010 RX TABLET, EXTENDED RELEASE ORAL 8440703 April 8, 2025 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
10MG AMPYRA ACORDA N022250 Jan. 22, 2010 RX TABLET, EXTENDED RELEASE ORAL 8354437 Dec. 22, 2026 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
10MG AMPYRA ACORDA N022250 Jan. 22, 2010 RX TABLET, EXTENDED RELEASE ORAL 8007826 May 26, 2027 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-gated potassium channel Ion channel BLOCKER CHEMBL CHEMBL
Potassium voltage-gated channel subfamily C member 1 Unclassified BLOCKER IC50 4.50 IUPHAR
Potassium voltage-gated channel subfamily C member 2 Unclassified BLOCKER IC50 4.60 IUPHAR

External reference:

IDSource
2416 IUPHAR_LIGAND_ID
4029704 VUID
N0000180628 NUI
C0000477 UMLSCUI
D04127 KEGG_DRUG
CHEMBL284348 ChEMBL_ID
80994002 SNOMEDCT_US
413355004 SNOMEDCT_US
NOCODE MMSL
4025700 VANDF
4025705 VANDF
897018 RXNORM
26967 MMSL
d07546 MMSL
4029704 VANDF
N0000167244 NDFRT
N0000180628 NDFRT
N0000176193 NDFRT
N0000176063 NDFRT
006829 NDDF
BH3B64OKL9 UNII
7283 INN_ID
DB06637 DRUGBANK_ID
1727 PUBCHEM_CID
D015761 MESH_DESCRIPTOR_UI
CHEBI:34385 CHEBI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
AMPYRA HUMAN PRESCRIPTION DRUG LABEL 1 10144-427 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL NDA 18 sections